NASDAQ: NEUP
Neuphoria Therapeutics Inc Stock

$4.94+0.01 (+0.2%)
Updated May 8, 2025
NEUP Price
$4.94
Fair Value Price
$0.05
Market Cap
$8.68M
52 Week Low
$2.12
52 Week High
$15.24
P/E
-1.93x
P/B
1x
P/S
13.13x
PEG
N/A
Dividend Yield
N/A
Revenue
$416.80k
Earnings
-$1.78M
Gross Margin
100%
Operating Margin
-483.45%
Profit Margin
-433.3%
Debt to Equity
0.32
Operating Cash Flow
-$5M
Beta
0.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

NEUP Overview

Bionomics Ltd is a clinical-stage biopharmaceutical company focused on drug candidates to transform the lives of patients suffering from serious central nervous system disorders. The company's lead candidate, BNC210, is a treatment for Social Anxiety Disorder and Post-Traumatic Stress Disorder. Bionomics was incorporated in 1996 and is based in Eastwood, Australia.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine NEUP's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
NEUP
Ranked
#144 of 457

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important NEUP news, forecast changes, insider trades & much more!

NEUP News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NEUP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NEUP ($4.94) is overvalued by 9,169.25% relative to our estimate of its Fair Value price of $0.05 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NEUP ($4.94) is not significantly undervalued (9,169.25%) relative to our estimate of its Fair Value price of $0.05 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NEUP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NEUP due diligence checks available for Premium users.

Valuation

NEUP fair value

Fair Value of NEUP stock based on Discounted Cash Flow (DCF)

Price
$4.94
Fair Value
$0.05
Overvalued by
9,169.25%
NEUP ($4.94) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NEUP ($4.94) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NEUP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NEUP price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-1.93x
Industry
-168.76x
Market
24.22x

NEUP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1x
Industry
4.15x
NEUP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NEUP's financial health

Profit margin

Revenue
$411.6k
Net Income
-$1.2M
Profit Margin
-293.2%
NEUP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NEUP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$11.3M
Liabilities
$2.7M
Debt to equity
0.32
NEUP's short-term assets ($2.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NEUP's short-term assets ($2.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NEUP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.1M
Investing
$0.0
Financing
-$69.3k
NEUP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NEUP vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
NEUPC$8.68M+0.14%-1.93x1.00x
BTAID$8.67M+3.27%-0.07x-0.09x
DWTXF$8.71M-1.51%-0.36x-0.86x
INTS$8.62M+3.09%-0.49x2.96x
PHIOC$8.60M-11.76%-0.20x1.82x

Neuphoria Therapeutics Stock FAQ

What is Neuphoria Therapeutics's quote symbol?

(NASDAQ: NEUP) Neuphoria Therapeutics trades on the NASDAQ under the ticker symbol NEUP. Neuphoria Therapeutics stock quotes can also be displayed as NASDAQ: NEUP.

If you're new to stock investing, here's how to buy Neuphoria Therapeutics stock.

What is the 52 week high and low for Neuphoria Therapeutics (NASDAQ: NEUP)?

(NASDAQ: NEUP) Neuphoria Therapeutics's 52-week high was $15.24, and its 52-week low was $2.12. It is currently -67.59% from its 52-week high and 132.58% from its 52-week low.

How much is Neuphoria Therapeutics stock worth today?

(NASDAQ: NEUP) Neuphoria Therapeutics currently has 1,757,027 outstanding shares. With Neuphoria Therapeutics stock trading at $4.94 per share, the total value of Neuphoria Therapeutics stock (market capitalization) is $8.68M.

Neuphoria Therapeutics stock was originally listed at a price of $176.76 in Dec 16, 2021. If you had invested in Neuphoria Therapeutics stock at $176.76, your return over the last 3 years would have been -97.21%, for an annualized return of -69.65% (not including any dividends or dividend reinvestments).

How much is Neuphoria Therapeutics's stock price per share?

(NASDAQ: NEUP) Neuphoria Therapeutics stock price per share is $4.94 today (as of May 8, 2025).

What is Neuphoria Therapeutics's Market Cap?

(NASDAQ: NEUP) Neuphoria Therapeutics's market cap is $8.68M, as of May 9, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Neuphoria Therapeutics's market cap is calculated by multiplying NEUP's current stock price of $4.94 by NEUP's total outstanding shares of 1,757,027.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.